1. Home
  2. ENHA vs VNDA Comparison

ENHA vs VNDA Comparison

Compare ENHA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enhanced Group Inc. Class A Common Stock

ENHA

Enhanced Group Inc. Class A Common Stock

N/A

Current Price

$2.78

Market Cap

375.7M

ML Signal

N/A

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$5.10

Market Cap

361.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENHA
VNDA
Founded
N/A
2002
Country
Singapore
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.7M
361.4M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
ENHA
VNDA
Price
$2.78
$5.10
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.90
AVG Volume (30 Days)
557.9K
810.4K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$216,105,000.00
Revenue This Year
N/A
$21.35
Revenue Next Year
N/A
$37.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.72
52 Week Low
$2.39
$4.14
52 Week High
$4.60
$9.91

Technical Indicators

Market Signals
Indicator
ENHA
VNDA
Relative Strength Index (RSI) 36.88 32.17
Support Level $2.53 N/A
Resistance Level $2.99 $5.46
Average True Range (ATR) 0.32 0.21
MACD 0.03 -0.04
Stochastic Oscillator 21.12 9.72

Price Performance

Historical Comparison
ENHA
VNDA

About ENHA Enhanced Group Inc. Class A Common Stock

Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: